A Study of Baricitinib (LY3009104) in Participants With Severe or Very Severe Alopecia Areata

Inclusion Criteria:

• Are at least 18 years and ≤60 years for males (≤70 years of age for females) at thetime of informed consent.

• Must self-identify as either Black or African American in race in the open labeladdenda.

• Have severe or very severe AA, as determined by all of the following:

• Current AA episode of more than 6 months' duration and hair loss encompassing ≥50% of the scalp, as measured by SALT Alopecia Areata Investigator GlobalAssessment (AA-IGA) of 3 or 4) at screening and baseline.

• No spontaneous improvement over the past 6 months.

• Current episode of severe or very severe AA of less than 8 years.

• Male or nonpregnant, nonbreastfeeding female participants.

Exclusion Criteria:

• Primarily "diffuse" type of AA.

• Are currently experiencing other forms of alopecia or any other concomitantconditions that would interfere with evaluations of the effect of study medicationon AA.

• Previously treated with an oral Janus kinase (JAK) inhibitor and had an inadequateresponse (for example, absence of significant terminal hair growth after at least 12weeks of treatment).